Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Drops By 48.7%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 543,884 shares, a decrease of 48.7% from the November 30th total of 1,060,995 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 1,476,646 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 1,476,646 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.5% of the shares of the stock are sold short.

VolitionRX Stock Down 0.8%

Shares of NYSEAMERICAN VNRX traded down $0.00 during midday trading on Friday, hitting $0.25. The stock had a trading volume of 695,210 shares, compared to its average volume of 1,963,337. The stock has a 50 day simple moving average of $0.34 and a 200-day simple moving average of $0.55. The company has a market capitalization of $30.70 million, a PE ratio of -1.09 and a beta of 1.26. VolitionRX has a 1 year low of $0.23 and a 1 year high of $0.94.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.